Sulfatase variant for improved hydrolysis of sulfated DHEAS

Sulfazyme™ is a collection of recombinant arylsulfatases engineered to hydrolyze steroid sulfates. There are three different arylsulfatases under this brand: Sulfazyme PaS (04E-270-005), Sulfazyme DS (04E-199-005) and Sulfazyme β–AS (04E-200-005). Compared to crude snail sulfatase, Sulfazyme PaS had fivefold higher recovery of terbutaline from human urine samples containing terbutaline sulfate as reported by Wang et al. (2018). Additionally, Lessard-Lord et al. (2021, 2023) used Sulfazyme PaS for room temperature hydrolysis of flavan-3-ol biomarkers and phenyl-γ-valerolactones in human urine samples; overall, sample incubation was reduced from six hours to five minutes relative to previous protocols. A new variant of Sulfazyme PaS, called Sulfazyme DS, has been genetically engineered for enhanced hydrolysis of dehydroepiandrosterone 3β-sulfate (DHEAS). Sulfazyme DS exhibits 7x and 38x higher activity towards cortisol 21-sulfate and DHEAS than Sulfazyme PaS, respectively.

DOWNLOAD OUR APPLICATION NOTE

Learn about the Sulfatase variant that has been genetically engineered for enhanced hydrolysis of DHEAS!

Frequently Asked Questions

Need help? Check out our FAQ section below or contact us for immediate assistance!

Caleb R. Schlachter, Ph.D.

Principal Scientist

Caleb R. Schlachter, Ph.D., as the Principal Scientist at IMCS, leads and provides guidance for several research and development projects that involve proteins, including enzymes for glycan hydrolysis and glycan synthesis. He has co-authored multiple patents, posters, and peer-reviewed articles on β-glucuronidases and sulfatases.

Gray D. Amick, Ph.D.

Director of Operations

Gray D. Amick, Ph.D., is the Director of Operations at IMCS with over 26 years of experience in forensic DNA analysis and toxicology. Prior to joining IMCS, he led forensic DNA testing for the Richland County Sheriff’s Department as technical leader and lab director. He has been court-qualified as an expert over 100 times and has authored and co-authored multiple posters and peer-reviewed articles.

Amanda C. McGee

Research Scientist

Amanda C. McGee is a Research Scientist at IMCS involved with enzyme characterizations, new analytical method developments, and advanced technical support. She joined IMCS with several years of experience in analytical testing for active pharmaceutical ingredients as per cGMP, USP and ICH guidelines. She has co-authored peer reviewed articles in the Journal of Analytical Toxicology and presented research at national and international conferences.

L. Andrew Lee, Ph.D.

Co-Founder and Chief Scientific Officer

L. Andrew Lee, Ph.D. co-founded IMCS and leads research and development efforts in enzyme engineering and automated micro-chromatography workflows. He directs new market efforts in glycan synthesis, supported by three NIH Fast-Track awards.

Sulfatase variant for improved hydrolysis of sulfated dehydroepiandrosterone (DHEAS)